Recent advances in understanding and treating vasculitis [version 1; referees

2 approved]

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.

Original languageEnglish (US)
Article number1436
JournalF1000Research
Volume5
DOIs
StatePublished - 2016

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Therapeutics
Monoclonal Antibodies
Cells
Cell- and Tissue-Based Therapy
B-Lymphocytes
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{11c3a89bd7bd486bb8e760ba538619f6,
title = "Recent advances in understanding and treating vasculitis [version 1; referees: 2 approved]",
abstract = "Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.",
author = "Matthew Koster and Warrington, {Kenneth J}",
year = "2016",
doi = "10.12688/F1000RESEARCH.8403.1",
language = "English (US)",
volume = "5",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in understanding and treating vasculitis [version 1; referees

T2 - 2 approved]

AU - Koster, Matthew

AU - Warrington, Kenneth J

PY - 2016

Y1 - 2016

N2 - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.

AB - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.

UR - http://www.scopus.com/inward/record.url?scp=85010991079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010991079&partnerID=8YFLogxK

U2 - 10.12688/F1000RESEARCH.8403.1

DO - 10.12688/F1000RESEARCH.8403.1

M3 - Review article

VL - 5

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 1436

ER -